BPA Call 36C25222A0035-36C25223N0480
Award Date
7/15/23
Potential Completion Date
7/14/24
Potential Value
$1.4M
Federal Agency
Veterans Integrated Service Network 12
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10007, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used for prostate cancer positron emission tomography (PET) imaging. The contract, valued at $765,048.64, has a period of performance through February 29, 2024. PYLARIFY is the flagship product of Progenics Pharmaceuticals, a pharmaceutical company...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed price Blanket Purchase Agreement (BPA) call worth $632,442.60 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY, a radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging of prostate cancer. This BPA, which is associated with the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), allows various VA medical...
The U.S. Department of Veterans Affairs (VA) awarded a Firm Fixed Price contract worth $1,732,185.60 to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY Injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. This contract is a Blanket Purchase Agreement (BPA) call under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The BPA was...
The Department of Veterans Affairs (VA) awarded a $538,099.28 firm-fixed-price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the radiopharmaceutical product PYLARIFY (piflufolastat F-18). PYLARIFY is a diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is not set aside and is part of a larger Blanket Purchase Agreement (BPA) valued at $5.5 million, which facilitates the...
The U.S. Department of Veterans Affairs (VA) awarded a $649,736.50 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract was awarded under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) call with a ceiling value of $902,180.00 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the procurement of PYLARIFY, a radiopharmaceutical used in positron emission tomography (PET) scans to detect and image prostate cancer. This BPA call was issued under the Pharmaceuticals and Drugs Federal Supply Schedule...
The Department of Veterans Affairs (VA) awarded a $742,556 firm-fixed-price delivery order to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the supply of PYLARIFY F-18 injections, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. This delivery order is part of a larger Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs...
The U.S. Department of Veterans Affairs (VA) awarded a $925,328.45 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY, a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. This delivery order is part of a larger Blanket Purchase Agreement (BPA) with the VA, valued at $5.5 million, which facilitates the ongoing...
The Department of Veterans Affairs (VA) awarded Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., a $5,040,033.60 firm fixed price delivery order contract to provide PYLARIFY, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. This contract is part of the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is not set aside. The VA, through its various Veterans Integrated Service...
This is a firm fixed-price delivery order award by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The $400,000.00 contract is for the delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used in positron emission tomography (PET) scans to detect prostate cancer. The contract is under the VA's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs, and is not set aside for any particular business type....